The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Poor oral health (periodontal disease) impacts nearly 51% of Indians
India has taken the lead in recognising NAFLD as a major non-communicable disease
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
